Literature DB >> 26680059

Outcomes of Liver Transplantation During Adulthood After Kasai Portoenterostomy Due to Biliary Atresia.

J J Segura-Sampedro1, C Bernal-Bellido2, L M Marín-Gómez2, G Suárez-Artacho2, J Serrano-Díez-Canedo2, J M Álamo-Martínez2, F J Padillo-Ruiz2, M Á Gómez-Bravo2.   

Abstract

Biliary atresia (BA) is a neonatal progressive cholangiopathy of unknown etiology and one of the most common reasons for liver transplantation (LT) in children. Kasai portoenterostomy (KP) improves survival of the native liver, although LT remains the only ultimate treatment. In some cases KP makes it possible to defer the ultimate LT until adulthood. We report our experience regarding 5 cases of BA treated with LT during adulthood. KP was performed in all patients at an average age of 176 days (range, 60-280), which allowed an average survival of the native liver of 19.01 years (range, 14.06-22.32). Five-year survival rate was 100%. Ten-year survival rate did not reach 100% because of a death 9.55 years after LT due to chronic graft rejection, in a patient who was already prepared for a new LT. Our results corroborate that KP remains the first-line treatment of BA. Early performance of the KP provides children with the best chance of survival, allowing the delay of the LT to adulthood. LT during adulthood in these patients achieves good post-LT survival rate; we have not found any data regarding this group of patients in the literature.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26680059     DOI: 10.1016/j.transproceed.2015.09.058

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  1 in total

1.  Bowel perforation after liver transplantation for biliary atresia: a retrospective study of care in the transition from children to adulthood.

Authors:  Yusuke Yanagi; Toshiharu Matsuura; Makoto Hayashida; Yoshiaki Takahashi; Koichiro Yoshimaru; Genshirou Esumi; Tomoaki Taguchi
Journal:  Pediatr Surg Int       Date:  2016-11-23       Impact factor: 1.827

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.